A new analysis suggests that so-called “breakthrough” treatments for Alzheimer’s disease may not deliver meaningful benefits for patients, despite earlier optimism.
Researchers found that while these drugs can slow the progression of the disease, the effect is too small to significantly improve patients’ daily lives.
🧠 How these drugs work
The treatments target a protein known as beta amyloid, which builds up in the brain and is linked to Alzheimer’s. Scientists designed antibodies to detect and remove these deposits.
Recent drugs such as donanemab and lecanemab marked a major step forward. Clinical trials showed they could slow cognitive decline—something no previous treatment had achieved.
However, experts now question whether this slowing is enough to make a real difference in everyday functioning.
📊 What the research found
The Cochrane Collaboration reviewed 17 studies involving over 20,000 participants. Their conclusion: although the drugs reduce disease progression, the benefit remains “well below” what patients need to notice meaningful improvement.
⚠️ Risks and limitations
These treatments also come with drawbacks. Patients may face side effects such as brain swelling and bleeding. In addition, the drugs require regular infusions every two to four weeks.
Cost is another major barrier. A full course of treatment can cost around £90,000, making it inaccessible for most people without public healthcare coverage.
Currently, the NHS does not fund these medications, further limiting availability.
🔬 Scientific debate continues
The report has sparked strong reactions within the scientific community. Some experts argue the findings underestimate the importance of even small improvements in slowing Alzheimer’s progression. Others support the conclusion that the benefits do not justify the risks and costs.
❓ What it means for patients
While these drugs represent scientific progress, their real-world impact remains uncertain. Patients and families must weigh potential benefits against risks, costs, and the limited improvement in quality of life.
As research continues, scientists hope future treatments will deliver more substantial results for those living with Alzheimer’s.
